Reganni (Regorafenib 40mg) Rx
৳ 5,510.05
TLPH pharma
Generic Regorafenib
Pack Size: 28’s Pot
Form: Tablet
Regorafenib, (Reganni) works for treating colorectal cancer, advanced gastrointestinal stromal tumours (GIST), hepatocellular carcinoma (HCC). Regorafenib prevents the growth of tumors. Regorafenib is a doctor prescription (Regorafenib) medicine.
TLPH Pharma Ltd. in laos mfg Reganni.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Reganni tablet may be taken with or without food, but it is better to take it at a fixed time.
Suggestion:
Genuine medicine is important for treatment. So, always try to source genuine medicines from authentic sources and check the quality of medicines.
Side effects:
The most common side effects of Regorafenib are:
Diarrhea, pain/sores in the mouth/throat, changes in taste, dry mouth, loss of appetite, hair loss, voice changes, weight loss, or muscle stiffness. Tell your doctor or pharmacist right away if any of these side effects persist or worsen.
Remember that your doctor has prescribed this medication because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Tell your doctor right away if you have any serious side effects, including: slow wound healing, signs of dehydration (such as extreme thirst, dizziness, decreased urination), signs of mineral imbalance (such as muscle cramps/weakness, irregular heartbeat, mental/mood changes), signs of infection (such as fever, chills, persistent sore throat), signs of underactive thyroid (weight gain, cold intolerance, unusual tiredness, slow heartbeat).
Take this medication regularly to get the most benefit from it. To help you remember, take it at the same times on the days your doctor directs.
This is not a complete list of possible side effects. Contact your doctor or pharmacist if you have any other side effects not listed above.

Reviews
There are no reviews yet.